scholarly journals A Six Year Follow-up Study on the Influence of Silent Ischemic Brain Lesions on Cognitive Function and Brain Atrophy in Elderly People.

2000 ◽  
Vol 37 (4) ◽  
pp. 298-303 ◽  
Author(s):  
Hiroaki Oguro ◽  
Kazunori Okada ◽  
Shuhei Yamaguchi ◽  
Shotai Kobayashi
Keyword(s):  
Cognitive Function ◽  
Elderly People ◽  
Brain Atrophy ◽  
Brain Lesions ◽  
Ischemic Brain ◽  
Follow Up Study

Long‐term effects of rice‐farming care on cognitive function and mental health of elderly people with cognitive impairment: a follow‐up study

2019 ◽  
Vol 19 (5) ◽  
pp. 513-515
Author(s):  
Sachiko Yamazaki ◽  
Chiaki Ura ◽  
Tsuyoshi Okamura ◽  
Masaya Shimmei ◽  
Taichi Ishiguro ◽  
...  
Keyword(s):  
Mental Health ◽  
Cognitive Impairment ◽  
Cognitive Function ◽  
Elderly People ◽  
Rice Farming ◽  
Long Term Effects ◽  
Follow Up Study

ALDH2 modulated changes in cytokine levels and cognitive function in bipolar disorder: A 12-week follow-up study

2017 ◽  
Vol 52 (7) ◽  
pp. 680-689
Author(s):  
Sheng-Yu Lee ◽  
Tzu-Yun Wang ◽  
Shiou-Lan Chen ◽  
Yun-Hsuan Chang ◽  
Po-See Chen ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Cognitive Function ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Follow Up Study ◽  
Cytokine Levels

Objectives: We investigated the association of the aldehyde dehydrogenase 2 ( ALDH2) polymorphism (rs671), which is involved with the dopaminergic function, and with changes in cytokine levels and cognitive function, in a 12-week follow-up study in patients with bipolar disorder. Methods: Patients with a first diagnosis of bipolar disorder were recruited. Symptom severity and levels of plasma cytokines (tumor necrosis factor α, C-reactive protein, interleukin 6 and transforming growth factor β1) were examined during weeks 0, 1, 2, 4, 8 and 12. Neurocognitive function was evaluated at baseline and endpoint. The ALDH2 polymorphism genotype was determined. Results: A total of 541 patients with bipolar disorder were recruited, and 355 (65.6%) completed the 12-week follow-up. A multiple linear regression analysis showed a significant ( p = 0.000226) association between the ALDH2 polymorphism and changes in C-reactive protein levels. Different aspects of cognitive function improved in patients with different ALDH2 genotypes. Only patients with the ALDH2*1*1 genotype showed significant correlations between improvement of cognitive function and increased transforming growth factor -β1. Conclusion: The ALDH2 gene might influence changes in cytokine levels and cognitive performance in patients with bipolar disorder. Additionally, changes in cytokine levels and cognitive function were correlated only in patients with specific ALDH2 genotypes.

scholarly journals Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

2014 ◽  
Vol 85 (10) ◽  
pp. 1109-1115 ◽  
Author(s):  
Cecilie Jacobsen ◽  
Jesper Hagemeier ◽  
Kjell-Morten Myhr ◽  
Harald Nyland ◽  
Kirsten Lode ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Atrophy ◽  
Disability Progression ◽  
Follow Up Study ◽  
Multiple Sclerosis Patients

Abstract T P160: Influence of Polyunsaturated Fatty Acids on Cognition in Elderly Alzheimer's Disease Patients

Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
Takashi Yamazaki ◽  
Ken Nagata ◽  
Daiki Takano ◽  
Tetsuya Maeda
Keyword(s):  
Alzheimer’S Disease ◽  
Blood Pressure ◽  
Alzheimer's Disease ◽  
Cognitive Function ◽  
Mmse Score ◽  
Characteristic Curve ◽  
Follow Up Study ◽  
Cognitive Stability ◽  
The Relationship

Background: Many genes and environmental factors linked to Alzheimer’s disease (AD) risk affect lipid metabolism or the cardiovascular system, strongly implicating cerebrovascular and metabolic dysfunction in AD pathogenesis. Although some PUFAs may improve cognitive function in aging individuals, it is still unclear how different PUFAs influence AD neuropathology and cognitive function. Objective: To examine the influence of polyunsaturated fatty acid (PUFA) metabolism on AD-associated cognitive decline, we investigated the relationship between serum PUFA profile and neuropsychological test performance. Methods: Cognitive functioning in patients with probable AD (n = 174, mean age 77.6 years) was examined using the Mini-Mental State Exam (MMSE) and clock drawing test (CDT). Serum samples were obtained for PUFA profile, including the eicosapentaenoic acid/arachidonic acid (EPA/AA) ratio, and measurement of brain natriuretic peptide (BNP) concentration. In the follow-up study, 47 subjects repeated MMSE and CDT after 1 year, According to the second MMSE score, the subjects were divided into the following 2 groups: those with unchanged or improved MMSE score and those with lower MMSE score. A receiver operating characteristic curve was used to evaluate the relationship between the EPA/AA ratio and 1-year cognitive stability. Results: In the cross-sectional study, total MMSE score correlated positively with the EPA/AA ratio and systolic blood pressure (SBP), and negatively with age and diastolic blood pressure (DBP) (p < 0.05). In the follow-up study, the MMSE score was lower than baseline in 20 subjects, whereas it was improved or unchanged in 29 patients. The EPA/AA ratio in the stable group was significantly greater than that in the deteriorating group, suggesting an association between higher EPA/AA ratio and cognitive stability over 1 year. The EPA/AA ratio predicted stability of cognitive performance with a sensitivity of 66% and specificity of 70% (odds ratio = 4.43) when the cut-off was 0.67. Conclusion: Our results suggest that serum EPA concentration strongly influences cognitive performances in AD patients. The EPA/AA ratio was a sensitive indicator of cognitive stability in this patient group.

scholarly journals Cognitive Function and Mortality: Results from Kaunas HAPIEE Study 2006–2017

2020 ◽  
Vol 17 (7) ◽  
pp. 2397
Author(s):  
Abdonas Tamosiunas ◽  
Laura Sapranaviciute-Zabazlajeva ◽  
Dalia Luksiene ◽  
Dalia Virviciute ◽  
Martin Bobak
Keyword(s):  
Cognitive Function ◽  
Baseline Survey ◽  
Cardiovascular Disease Mortality ◽  
Follow Up Study ◽  
Kaplan Meier ◽  
Disease Mortality ◽  
Increased Risk ◽  
All Cause Mortality ◽  
Cvd Mortality

Background: The purpose of the study is to evaluate the association between cognitive function and risk of all-cause and cardiovascular disease mortality during 10 years of the follow-up. Methods: 7087 participants were assessed in the baseline survey of the Health Alcohol Psychosocial Factors in Eastern Europe (HAPIEE) study in 2006–2008. During 10 years of follow-up, all-cause and CVD mortality risk were evaluated. Results: During 10 years of follow-up, 768 (23%) men and 403 (11%) women died (239 and 107 from CVD). After adjustment for sociodemographic, biological, lifestyle factors, and illnesses, a decrease per 1 standard deviation in different cognitive function scores increased risk for all-cause mortality (by 13%–24% in men, and 17%–33% in women) and CVD mortality (by 19%–32% in men, and 69%–91% in women). Kaplan-Meier survival curves for all-cause and CVD mortality, according to tertiles of cognitive function, revealed that the lowest cognitive function (1st tertile) predicts shorter survival compared to second and third tertiles (p < 0.001). Conclusions: The findings of this follow-up study suggest that older participants with lower cognitive functions have an increased risk for all-cause and CVD mortality compared to older participants with a higher level of cognitive function.

The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study

2007 ◽  
Vol 13 (8) ◽  
pp. 1068-1070 ◽  
Author(s):  
L. Roccatagliata ◽  
MA Rocca ◽  
P. Valsasina ◽  
L. Bonzano ◽  
MP Sormani ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Atrophy ◽  
Marked Decrease ◽  
Hematopoietic Stem ◽  
Follow Up Study ◽  
Long Term Effect ◽  
Second Year ◽  
Multiple Sclerosis Patients

Using MRI, we measured disease activity and brain atrophy in nine multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT) for a mean follow up of 63 months. We show that AHSCT is associated to a longlasting suppression of inflammation and to a marked decrease of the rate of brain atrophy after the second year following treatment. Multiple Sclerosis 2007; 13 : 1068—1070. http://msj.sagepub.com

Sign in / Sign up

Export Citation Format

Share Document